Scientists identify protective role for antibodies in Ebola vaccine study

January 14, 2013, NIH/National Institute of Allergy and Infectious Diseases

Researchers at the National Institutes of Health (NIH) and Oregon Health & Science University (OHSU) have found that an experimental vaccine elicits antibodies that can protect nonhuman primates from Ebola virus infection.

Ebola virus causes severe hemorrhagic fever in humans and , meaning that infection may lead to shock, bleeding and multi-organ failure. According to the World Health Organization, Ebola hemorrhagic fever has a fatality rate of up to 90 percent. There is no licensed treatment or vaccine for Ebola virus infection.

Several research groups have developed approaches that protect nonhuman primates from Ebola virus and the closely related Marburg virus. These approaches include vaccines based on DNA, recombinant adenovirus, virus-like particles, and human parainfluenza virus 3. But how these vaccine candidates confer protection is an area that is still being explored: Do they activate immune cells to kill the invading virus? Or do they elicit antibodies that block infection?

In this study, scientists at NIH's National Institute of Allergy and Infectious Diseases and OHSU's Vaccine & Gene Therapy Institute built on earlier work with an experimental vaccine composed of an attenuated vesicular stomatitis virus carrying a gene that codes for an Ebola virus protein. They observed how cynomolgus macaques responded to a challenge of Ebola virus before and during treatment with the vaccine and in conjunction with depleted levels of immune cells. Their results showed that important immune cells—CD4+ T cells and CD8+ T cells—had a minimal role in providing protection, while antibodies induced by the vaccine appeared to be critical to protecting the animals.

The scientists say this finding will help improve future Ebola virus development. They plan to focus their studies on what level of antibody production is needed to establish protection from Ebola infection in humans.

Explore further: Ebola virus uses a protein decoy to subvert the host immune response

More information: A Marzi et al. Antibodies are necessary for rVSV/ZEBOV-GP mediated protection against lethal Ebola virus challenge in nonhuman primates. Proceedings of the National Academy of Sciences. DOI: 10.1073/pnas.1209591110 (2013).

Related Stories

Ebola virus uses a protein decoy to subvert the host immune response

December 13, 2012
In a study published today in the Open Access journal PLOS Pathogens, researchers at Emory University have discovered a potentially important mechanism by which the Ebola virus alters and evades the immune response of its ...

Combination vaccine protects monkeys from ebola and Marburg viruses

February 26, 2008
An experimental, combination vaccine against Ebola and Marburg viruses using virus-like particles (VLPs) provides complete protection against infection in monkeys. Researchers from the U.S. Army Medical Research Institute ...

Single vaccines to protect against both rabies and Ebola

August 25, 2011
Researchers from Thomas Jefferson University, among other institutions, including the National Institute of Allergy and Infectious Diseases, have developed single vaccines to protest against both rabies and the Ebola virus.

Vaccine for Ebola virus

March 31, 2008
One of the world’s deadliest diseases, caused by the Ebola virus, may finally be preventable thanks to US and Canadian researchers, who have successfully tested several Ebola vaccines in primates and are now looking to ...

Experimental Marburg vaccine prevents disease 2 days after infection

June 16, 2010
An experimental vaccine developed to prevent outbreaks of Marburg hemorrhagic fever continues to show promise in monkeys as an emergency treatment for accidental exposures to the virus that causes the disease. There is no ...

Experimental vaccine protects monkeys from new Ebola virus

May 20, 2010
New research has found that an experimental Ebola vaccine developed by researchers at the National Institutes of Health protects monkeys against not only the two most lethal Ebola virus species for which it was originally ...

Recommended for you

Study examines disruption of circadian rhythm as risk factor for diseases

December 11, 2018
USC scientists report that a novel time-keeping mechanism within liver cells that helps sustain key organ tasks can contribute to diseases when its natural rhythm is disrupted.

New light-based technology reveals how cells communicate in human disease

December 11, 2018
Scientists at the University of York have developed a new technique that uses light to understand how cells communicate in human disease.

Study may offer doctors a more effective way to treat neuroblastoma

December 7, 2018
A very large team of researchers, mostly from multiple institutions across Germany, has found what might be a better way to treat patients with neuroblastoma, a type of cancer. In their paper published in the journal Science, ...

Progress made in transplanting pig hearts into baboons

December 6, 2018
A large team of researchers from several institutions in Germany, Sweden, Switzerland and the U.S. has transplanted pig hearts into baboons and kept them alive for an extended period of time. In their paper published in the ...

'Chemo brain' caused by malfunction in three types of brain cells, study finds

December 6, 2018
More than half of cancer survivors suffer from cognitive impairment from chemotherapy that lingers for months or years after the cancer is gone. In a new study explaining the cellular mechanisms behind this condition, scientists ...

Hybrid prevalence estimation: Method to improve intervention coverage estimations

December 6, 2018
LSTM's Professor Joseph Valadez is senior author on a new study published today in the Proceedings of the National Academy of Sciences, which outlines proposals for a more accurate estimator of health data.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.